Discover What's
Next in
Cardiovascular Care.
Experience breakthrough Nanolute™ sirolimus-coated balloon technology — backed by landmark NEJM and JACC publications. Meet our experts at Booth F18, Paris.
Join Our Symposium
Deep dive into a session on sirolimus-coated balloon evidence and real-world procedural experience featuring global faculty with expert case discussions.
Where Evidence Meets Experience
Where Our Data Takes the Stage
Catch our investigators presenting the latest MagicTouch evidence across hotline sessions, late-breaking trials, abstracts and case corners throughout the congress.
Prevalence, temporal trends and characteristics of high bleeding risk patients in TRANSFORM II randomised controlled trial
Coronary bifurcation lesions side branch optimal treatment study: the BILBO multicentre study
DCB in STEMI: multicentre international registry
Sirolimus vs paclitaxel-coated balloons in STEMI: international multi-centre registry
DCB for CTO: final results of PICCOLETO X multicentre study
DES vs. DCB strategy in SVG PCI: real-world outcomes from two large UK centres
DCB in STEMI: multicentre international registry
Session times and locations are subject to change by the EuroPCR 2026 organising committee. All times shown in CEST (Central European Summer Time).
Revolutionizing Drug Delivery in Vascular Intervention
NANOLUTE technology delivers polymer-free nanocarriers containing sirolimus surrounded by an encapsulation of a proprietary phospholipid carrier — improving lipophilicity and ensuring deep vessel wall penetration.
- Facilitates better adhesion of Sirolimus on the balloon surface
- Circumferential coating ensures homogeneous drug delivery
- Effective drug transfer to the deepest layer of the vessel
- Better in-tissue bioavailability of Sirolimus
A Decade
of Evidence
From CE Mark to a still-growing clinical record across coronary and peripheral indications.
MagicTouch
It's repeatedly studied.
Landmark Clinical Results
Randomised controlled trials demonstrating superior outcomes across coronary and peripheral indications — from JACC to the New England Journal of Medicine.
1. Log–rank p=0.03 | HR 0.60 (95% CI, 0.36–0.97). Preliminary before CEC adjudication.
MALE: Major Adverse Limb Events
2. –4.9% (–8.5% to –1.3%) P<0.001 for noninferiority | P=0.009 for superiority. Median Unbiased Estimate (95% CI).
3. Data published in EuroIntervention Journal: DOI: 10.4244/EIJ-D-23-00966, Volume 20, Number 13.
Meet Our Experts
at Booth F18
Schedule time with our clinical and commercial team for a personalised demo, data review, or strategic discussion.